Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

GLP-1 drugs are reshaping how pharma interacts with patients:
marketing is more direct, digital, and consumer‑driven than in the past.

Search behavior has shifted from specific brands like Ozempic to the broader term "GLP-1," signaling patients are thinking in drug classes, not company brands.

Pharma and telehealth players (e.g., Hims) are investing heavily in mass‑market advertising and GLP‑1–focused programs, bypassing traditional PBMs and going straight to employers and consumers.

These drugs are changing consumer behavior beyond health—diet, alcohol use, fitness, and even aesthetics—so pharma and adjacent industries must integrate health, nutrition, and lifestyle messaging into their consumer relationships.

Regulators and industry watchers are paying close attention to how these drugs are marketed and sold, especially compounded versions, to ensure safety and fair balance in consumer‑facing ads.